Why is hydrocortisone administered to a patient with severe community‑acquired pneumonia in the intensive care unit?

Hydrocortisone in Severe CAP: When and Why to Use It

Hydrocortisone should be administered to patients with severe community-acquired pneumonia in the ICU primarily when they develop septic shock that remains unresponsive to adequate fluid resuscitation and vasopressor therapy, at a dose of 200 mg/day intravenously. 1

Primary Indication: Refractory Septic Shock

The clearest evidence-based indication for hydrocortisone in severe CAP is vasopressor-dependent septic shock (hypotension persisting despite fluid resuscitation and vasopressors for >60 minutes). 1 This recommendation comes from the Surviving Sepsis Campaign guidelines, which the 2019 ATS/IDSA CAP guidelines explicitly endorse. 2

Key Decision Point:

• If hemodynamic stability is restored with fluids and vasopressors alone: Do NOT use hydrocortisone 1
• If shock persists despite adequate resuscitation and vasopressors: Consider hydrocortisone 200 mg/day IV 1

Emerging Evidence for Severe CAP Without Shock

Recent high-quality evidence suggests broader benefit in severe CAP patients, even without refractory shock:

The 2023 CAPE COD trial (the most recent and highest quality study) demonstrated that hydrocortisone reduced 28-day mortality from 11.9% to 6.2% (absolute reduction of 5.6%) in ICU patients with severe CAP. 3 This landmark study also showed:

• Reduced need for intubation (18.0% vs 29.5%)
• Reduced vasopressor initiation (15.3% vs 25.0%)
• Similar infection and bleeding rates between groups

However, the 2025 REMAP-CAP trial contradicted these findings, showing no mortality benefit with a fixed 7-day hydrocortisone course and suggesting possible harm (15% vs 9.8% mortality, though not statistically significant). 4

Reconciling Conflicting Evidence

The divergent results likely reflect differences in:

• Dosing regimen: CAPE COD used response-guided duration (4-7 days with tapering), while REMAP-CAP used fixed 7-day course 3, 4
• Patient selection: CAPE COD excluded influenza; REMAP-CAP included it 3, 4
• Severity: CAPE COD patients may have been more severely ill

Meta-analyses support hydrocortisone specifically (not other corticosteroids) for mortality reduction in severe CAP. 5, 6

Practical Algorithm for ICU Severe CAP

1. Septic shock refractory to fluids + vasopressors:

   • USE hydrocortisone 200 mg/day IV (strong recommendation) 1
   • Continue until vasopressors no longer needed, then taper 1

2. Severe CAP without refractory shock but with high inflammatory burden:

   • CONSIDER hydrocortisone based on CAPE COD evidence 3
   • Best candidates: High CRP, severe hypoxemia, not influenza 7
   • Dose: 200 mg/day IV for 4-7 days based on clinical response, followed by taper 3

3. Influenza pneumonia:

   • Avoid routine corticosteroids (may increase mortality) 2

4. Sepsis without shock:

   • Do NOT use corticosteroids 1

Administration Details

• Route: Continuous IV infusion preferred over bolus dosing (reduces hyperglycemia peaks) 1
• Dose: 200 mg/day (can give as 50 mg every 6 hours or continuous infusion) 1, 8
• Duration: 4-7 days at full dose based on clinical improvement, then taper over equal duration 3
• Taper: When vasopressors discontinued; avoid abrupt cessation 1

Mechanism of Benefit

Hydrocortisone works through:

• Attenuating excessive systemic inflammation 9
• Correcting relative adrenal insufficiency (inadequate stress response) 1, 10
• Improving vasopressor responsiveness 1
• Modulating immune response without complete immunosuppression 8

Critical Caveats

Avoid etomidate for intubation in these patients—it suppresses the hypothalamic-pituitary-adrenal axis and was associated with increased 28-day mortality when combined with steroids. 1

Monitor closely for:

• Hyperglycemia (most common side effect—maintain tight glucose control) 1, 10
• Hypernatremia (especially with prolonged use >48-72 hours) 8
• Secondary infections (though not clearly increased in trials) 3, 6

Type matters: Hydrocortisone specifically shows mortality benefit; dexamethasone, methylprednisolone, and prednisolone do not demonstrate the same effect in severe CAP. 5

Bottom Line

The strongest indication remains refractory septic shock where guidelines are clear. For severe CAP without refractory shock, the 2023 CAPE COD trial provides compelling evidence for benefit 3, though the 2025 REMAP-CAP trial urges caution 4. Given the favorable safety profile at 200 mg/day with appropriate monitoring, and the significant mortality reduction in CAPE COD, hydrocortisone is reasonable in severe CAP requiring ICU admission, particularly with high inflammatory markers and non-influenza etiology, while avoiding routine use in less severe cases or influenza pneumonia.